ストックスクリーナーアプリを入手
24.11
1.69%
0.395
前日終値:
$23.72
開ける：
$24.05
24時間の取引高:
15.20M
Relative Volume:
0.39
時価総額：
$137.39B
収益：
$63.32B
当期純損益:
$7.52B
株価収益率:
18.49
EPS:
1.3043
ネットキャッシュフロー:
$9.48B
1週間 パフォーマンス:
+0.16%
1か月 パフォーマンス:
-7.37%
6か月 パフォーマンス:
-4.59%
1年 パフォーマンス:
-4.44%
1日の値動き範囲:
$24.05
$24.35
1週間の範囲:
$23.62
$24.57
52週間の値動き範囲:
$23.11
$28.75
Pfizer Inc Stock (PFE) Company Profile
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.11 | 138.61B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,237.33 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
268.25 | 633.19B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
257.32 | 461.26B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
129.05 | 319.99B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
157.27 | 305.10B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-02 | アップグレード | Argus | Hold → Buy |
| 2026-02-25 | 開始されました | RBC Capital Mkts | Underperform |
| 2026-02-20 | 開始されました | Barclays | Underweight |
| 2026-02-12 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-02 | 再開されました | Citigroup | Neutral |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-25 | 再開されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | ダウングレード | Argus | Buy → Hold |
| 2024-02-23 | 開始されました | Guggenheim | Buy |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-10-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-17 | 繰り返されました | JP Morgan | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | ダウングレード | UBS | Buy → Neutral |
| 2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-13 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-20 | 繰り返されました | Cowen | Outperform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-13 | アップグレード | UBS | Neutral → Buy |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
| 2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 再開されました | Goldman | Neutral |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 再開されました | Morgan Stanley | Overweight |
| 2019-02-20 | 再開されました | Citigroup | Neutral |
| 2019-01-31 | アップグレード | Argus | Hold → Buy |
| 2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | ダウングレード | UBS | Buy → Neutral |
| 2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential? - TradingView
Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider - GlobeNewswire Inc.
Pfizer Inc. outlines long-term growth drivers as a global healthcare leader - AD HOC NEWS
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Pfizer Inc. stock underperforms Monday when compared to competitors - MarketWatch
Pfizer's Growth Story Faces a Wait as Pipeline and Leadership Doubts Mount - Benzinga
Pfizer Trades at Just 8.5x Earnings While Peers Fetch 16x. Is the Discount Justified? - TIKR.com
HSBC Drops Pfizer to Hold: Seagen ADC Miss Leaves $43B Bet Without Catalyst - Tech Times
Price to earnings forward of Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S – TSX:PFE - TradingView
Pfizer (PFE) Wins FDA Approval For IBRANCE In HER2 Positive Breast Cancer - Yahoo Finance
Analyst recommendations: Chubb, Delta Air Lines, Pfizer, AMD, Dow… - marketscreener.com
HSBC Downgrades Pfizer to Hold From Buy, Adjusts Price Target to $28 From $32 - marketscreener.com
This M&T Bank Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
HSBC downgrades Pfizer stock rating on lack of near-term catalysts - Investing.com
Pfizer, Inc. (PFE) Stock Analysis: Exploring a 19.86% Potential Upside Amid Strong Dividend Yield - DirectorsTalk Interviews
Pfizer Inc. (PFE): A Top Dividend Stock to Buy According to Hedge Funds amid Ibrance FDA Milestone - Insider Monkey
Pfizer Inc. - Encyclopedia Britannica
PFEPfizer Inc Volatility & Greeks - Finviz
ETFs Investing in Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs Stocks - TradingView
Pfizer Stock’s Dividend Yield Sits at 7% Heading Into the Back Half of 2026 - TIKR.com
PFIZER INC : Buy rating from Jefferies - marketscreener.com
Pfizer's CEO Says His Company Has a "Very Big Balance Sheet" to Do Deals. Here's the Perfect Next Acquisition Target for the Pharma Giant. - Yahoo Finance
Pfizer (PFE) Stock May Be Fairly Priced On Its 22% Slide - simplywall.st
Pfizer CEO on primary care, GLP-1 outlook and innovation timeline - AOL.com
Form 4 Pfizer For: 1 July By Investing.com - Investing.com Canada
Pfizer Inc. focuses on long-term therapies as investors watch the stock - AD HOC NEWS
Can Pfizer (NYSE:PFE) Advance Its Next-Generation Oncology Pipeline? - Kalkine Media
Pfizer Expands Migraine Strategy With New Rimegepant Redosing Study - TipRanks
Pfizer vs Verizon Communications: Which High-Yielding Dividend Stock Is the Better Buy? - Yahoo Finance
June Social Media Round-Up—2025 Impact Report, ADA 2026, and More - Pfizer
Is Pfizer (PFE) Stock Undervalued Despite Mixed Oncology Progress? - Yahoo Finance
Nike Appoints Pfizer CFO as New Finance Chief Amid Industry Experience Questions - marketscreener.com
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Pfizer Inc. stock outperforms competitors despite losses on the day - MarketWatch
Pfizer (NYSE:PFE) yield tops 7% after stock falls on China GLP-1 news - TechStock²
Form 4 Pfizer For: 30 June By Investing.com - Investing.com Canada
Pfizer-BioNTech COVID-19 Vaccine from Pfizer Inc.mRNA shot anchoring US immunization plans - AD HOC NEWS
Why Pfizer Could Prove to Be an Underrated GLP-1 Stock - The Globe and Mail
Pfizer Inc (NYSE:PFE) Reshapes Healthcare Pipeline Through Dealmaking - Kalkine Media
Pfizer opens the week with a clear earnings calendar, shares on NYSE in focus - AD HOC NEWS
Parasite Cleanse Market to See Booming Growth 2026-2033 | Bayer AG, Pfizer Inc., Merck & Co., Inc. - openPR.com
The Paxlovid tablets from Pfizer Inc.antiviral course that fits into daily routine - AD HOC NEWS
Why Is Pfizer (NYSE:PFE) Catching Value Stock Attention? - Kalkine Media
PFE Stock Quote Price and Forecast - CNN
Will FDA’s New IBRANCE (palbociclib) Maintenance Approval Reshape Pfizer’s (PFE) Oncology Narrative? - simplywall.st
Pfizer, Innovent GLP-1 drugs clear China insurance hurdle - Reuters
Is Pfizer Inc. (PFE) A Good Stock To Buy Now? - Insider Monkey
Pfizer muted in pharma sector comparison, shares trail S&P 500 peers - AD HOC NEWS
Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review - Yahoo Finance
Pfizer’s CFO Just Left and a Key Drug Trial Missed. Here’s What That Means for PFE Stock in 2026 - TIKR.com
China surpassing Europe in Drug Innovation and Development, Pfizer Inc. (PFE) Executive says - Insider Monkey
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
Pfizer Inc (PFE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SAHNI PAYAL | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
82,816 |
| LANKLER DOUGLAS M | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
122,907 |
4,156,715 |
282,186 |
| DAMICO JENNIFER B. | SVP & Controller |
Feb 25 '26 |
Option Exercise |
33.82 |
17,558 |
593,812 |
29,744 |
| BOURLA ALBERT | Chairman & CEO |
Feb 25 '26 |
Option Exercise |
33.82 |
491,626 |
16,626,791 |
864,215 |
| Fonseca Lidia | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
101,579 |
| McDermott Michael | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
37,925 |
1,282,624 |
114,534 |
4.08%
大文字化:
|
ボリューム (24 時間):